Cabot vs Chemours
Chemours reported revenue of $5.8 billion in fiscal 2025, 1.6 times Cabot's $3.7 billion in fiscal 2025. Cabot's revenue fell 7.0% in its latest year, and Chemours' grew 0.5%. Free cash flow was $391 million at Cabot and $51 million at Chemours. Their fiscal years end in different months (September 30 and December 31), so the periods don't line up exactly.
Side by side
| Cabot | Chemours | |
|---|---|---|
| Latest fiscal year | FY2025, Sep 30, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $3.7B | $5.8B |
| Revenue growth | −7.0% | 0.5% |
| Revenue growth a year, last 5 years | 7.3% | 3.2% |
| Gross margin | 25.3% | 15.5% |
| Operating margin | 16.7% | — |
| Net margin | 8.9% | −6.7% |
| Free cash flow | $391M | $51M |
| Free cash flow margin | 10.5% | 0.9% |
| Return on capital | 15.9% | −0.2% |
| Net debt to EBITDA | 1.1x | 10.6x |
| Dividends and buybacks | $264M | $78M |
| Change in diluted share count | −2.7% | 0.0% |
| Last close | $72.88 | $12.87 |
| P/E at the last close | 12.7× | — |
| Insider trades, last 12 months | sold $19.6 million | bought $488,650, sold $0 |
| Piotroski F-score | 6 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CabotChemours
Operating margin
Percent of revenue
CabotChemours
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CabotChemours